FibroGen (NASDAQ:FGEN) Posts Quarterly Earnings Results, Hits Expectations

FibroGen (NASDAQ:FGEN) posted its earnings results on Monday. The biopharmaceutical company reported ($0.08) EPS for the quarter, meeting analysts’ consensus estimates of ($0.08), Zacks reports. The business had revenue of $3.14 million during the quarter, compared to analysts’ expectations of $24.91 million.

FibroGen Stock Down 22.7 %

NASDAQ FGEN traded down $0.10 during trading on Tuesday, hitting $0.34. The stock had a trading volume of 2,859,751 shares, compared to its average volume of 2,323,324. The company has a market capitalization of $34.66 million, a PE ratio of -0.28 and a beta of 0.82. The firm has a 50 day moving average price of $0.51 and a 200 day moving average price of $0.43. FibroGen has a twelve month low of $0.18 and a twelve month high of $2.80.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on FGEN. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of FibroGen in a report on Tuesday. StockNews.com initiated coverage on shares of FibroGen in a research note on Friday. They issued a “hold” rating on the stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.